Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2013, Article ID 310628, 16 pages
http://dx.doi.org/10.1155/2013/310628
Review Article

Efficacy and Safety of Iguratimod for the Treatment of Rheumatoid Arthritis

1West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China
2Department of Rheumatology and Immunology, The First People’s Hospital of Yibin, Yibin, Sichuan 644000, China
3Department of Otolaryngology, The First People’s Hospital of Yibin, Yibin, Sichuan 644000, China
4The Chinese Cochrane Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China
5Department of Rheumatology and Clinical Immunology, The First Affiliated Hospital of Xiamen University, Xiamen 361003, China

Received 1 May 2013; Revised 15 September 2013; Accepted 18 September 2013

Academic Editor: Xuan Zhang

Copyright © 2013 Jiangtao Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

All randomized controlled trials (RCTs) of iguratimod for rheumatoid arthritis (RA) to assess its efficacy and safety are included in this paper. The Review Manager software was used for meta-analysis to assess risk bias of the studies included, and GRADE profiler software was used for the evidence quality of the studies included. Four RCTs involving 1407 patients with RA were included. Meta-analyses showed that, after 24-week therapy, ACR20, tender joint count, swollen joint count, rest pain, physician and patient global assessment of disease activity, HAQ score, ESR, and CRP in iguratimod group were better than those in placebo group and that the difference between those of iguratimod group and those of other DMARDs (MTX and SASP) group was not significant. GRADE evidence classification of the studies included was moderate. Iguratimod for RA had few adverse events, and its efficacy and safety were the same as those of MTX and SASP for RA. The results of this systematic review suggest that more high-quality and large-scaled RCTs were needed to determine the efficacy of iguratimod for RA and whether iguratimod is as effective as other DMARDs besides MTX and SASP.